Credit: Pixabay/CC0 Public Domain
In patients with blocked arteries, the largest analysis of the best “bad” cholesterol levels of “bad” cholesterol levels shows that statins only need to provide a combination of other drugs, Starin and Ezetimibe. This can prevent thousands of deaths a year with heart attack, stroke and other cardiovascular diseases.
In 14 studies that are very risk of suffering from heart attack or stroke or already experienced such cardiovascular events, the meta -analysis of 108,353 patients is presented in the journal. Mayo Clinic procedure.
When Ezev was combined with high dose statins to reduce the level of high-dose lipoprotein cholesterol (LDL-C), the risk of death due to all causes was reduced by 19%, and 16% reduction in cardiovascular causes, and compared to each major side effect compared to the main side effects of each major side effect of each cardiovascular case or 17% of each cardiovascular event. It shows that a decrease has occurred. Alone.
Combination therapy also significantly reduced LDL-C levels by 13 mg of blood per blood compared to statin alone measured from the baseline. This increased 85%of the likelihood of reaching the ideal goal of LDL-C’s 70 mg/dL.
“These results were more prominent in network meta analysis, which could be directly compared with the various treatment therapy used in the study. This showed that all cause mortality decreased by 49% and the main side effects decreased by 39%.” Johns Hopkins University School of Medicine Professor Ciccarone Center to prevent cardiovascular disease.
BANACH is also leading the blood pressure meta -analysis collaboration group that conducts research with international geological experts.
“The combination therapy is safe and effective, and the risks of side effects and the discontinuance rate of therapy were similar to the group. In network meta analysis, we have a significant reduction in the risk of interruption in high -dose doses and those treated alone with high doses and high -dose styles.”
So far, even before you have a heart attack or stroke, you have no results on whether you need to combine cholesterol reduction in high -risk patients before you have a heart attack or stroke, or if your doctor starts this patient first in a high doses statin and determines whether the patient needs an epem at least two months later There was an inconsistent consequences of whether to monitor the impact.
The co -author of this study, Peter Toth, Illinois University Clinical Family and Community Professor, and Medical Professor of Medical Medicine, a medical assistant professor at Johns Hopkins University, USA, should immediately consider treating cholesterol reduction that combines cholesterol forced treatment. Check that it should be a gold standard for the treatment of high -risk patients.
“In many patients, adding to the statin therapy without waiting for at least two months to see the effect of the next-line statin single therapy is associated with achieving more effective LDL-C goals and in charge of cardiovascular health problems and significant decrease in death.
“This approach does not require additional funds or repayment of new expensive drugs. In fact, it can be converted into complications such as initial and subsequent heart attack and stroke and complications such as heart failure, which is very expensive to all medical systems.”
According to the global burden of disease and data from the American Heart Association, the highest deaths occur with only high LDL-C in Eastern Europe and Central Asia. 4.5 million deaths worldwide It was due to that in 2020.
Professor BANACH said, “Cardiovascular disease is about 20 million people worldwide. Based on previous analysis, combined therapy for reducing LDL-C is believed to have been implemented by a doctor for patients with high cholesterol levels, and more than 330,000 patients who have already suffered heart attacks. It will prevent deaths and will prevent more than 330,000 of the 50,000 deaths.
“We should be considered as a gold standard for these patients and should be included in all future treatment guidelines.”
Statin has been safely used for several years. They help to lower LDL-C by reducing the production of IT by liver. Ezetimibe reduces the amount of cholesterol from the body by inhibiting the absorption of IT in the intestines.
Some patients do not respond appropriately to statins and are prescribed with statins. High dose statins are known as “high strength” statins, and moderately high doses are known as “intermediate strength” or “intermediate strength” statins.
“Our findings emphasize the importance of the dedication ‘, the lower the lower the lower the more, the more the lower the more you are to treat patients with high risk of cardiovascular state and avoid additional medical complications and death.”
The strength of the study is the largest patient that has been studied so far, so it is large. The patients were included in 14 studies, 11 of which were randomized tests and 3 were cohort studies.
Restrictions are mainly associated with the type of research, size and some observation characteristics included in meta -analysis.
Additional information:
Maciej Banach, et al. The effects of lipid reduction combination of statins and epilepsy treatment of cardiovascular results on the reduction of cardiovascular results: meta analysis, Mayo Clinic procedure (2025). Doi: 10.1016/J.Mayocp.2025.01.018
Provided by the Polish Lipid Association
recall: Two cholesterol decreased drugs can be combined to save thousands of lives.
This document is copyrighted. In addition to fair transactions for individual research or research purposes, you cannot reproduce any part without written permission. The contents are provided only for information purposes.
